# ğŸ§ª Liver Cirrhosis Survival Analysis

![Liver Cirrhosis](https://via.placeholder.com/1200x400.png?text=Liver+Cirrhosis+Survival+Analysis)

## ğŸ“– Overview  

This project investigates the **survival probabilities** of patients diagnosed with **liver cirrhosis** using advanced statistical techniques:  
âœ… **Kaplan-Meier survival curves**  
âœ… **Cox proportional hazards regression**  
âœ… **Survival probability estimation**  

The goal is to identify **key medical predictors**, compare treatment effects (**D-penicillamine vs. Placebo**), and offer recommendations for better **clinical decision-making**.  

---

## ğŸ¯ Study Objectives  

ğŸ” **Estimate Survival Probability:** Understand survival trends over time.  
ğŸ’Š **Compare Treatment Effects:** Determine effectiveness of **D-penicillamine** vs. **Placebo**.  
ğŸ“Š **Identify Key Predictors:** Analyze bilirubin, albumin, ascites, edema, and disease stage.  
ğŸ”¬ **Validate Cox Model Assumptions:** Ensure data fits proportional hazards assumptions.  
ğŸ“Œ **Offer Clinical Recommendations:** Use findings for better patient care.  

---

## ğŸ›  Technologies Used  

ğŸ”¹ **R** â€” Data analysis & modeling  
ğŸ”¹ **tidyverse** â€” Data wrangling & visualization  
ğŸ”¹ **survival** â€” Survival analysis models  
ğŸ”¹ **survminer** â€” Elegant visualizations  
ğŸ”¹ **flexsurv** â€” Advanced survival modeling  

---

## ğŸ“Š Data Overview  

ğŸ“Œ The dataset includes **276 participants** and tracks their medical condition.  
ğŸ©¸ **111 patients** died from liver cirrhosis during the study.  
ğŸ©º **Key variables:**  
   - `N_Days` â†’ Survival duration  
   - `Status` â†’ Deceased (`D`) or Censored (`C`)  
   - `Drug` â†’ **D-penicillamine** vs. **Placebo**  
   - `Age`, `Sex`, `Bilirubin`, `Albumin`, `Stage` â†’ Clinical indicators  

---

## ğŸ”¬ Key Findings  

### **Kaplan-Meier Survival Analysis**  
ğŸ“Œ **Median survival time:**  
   - ğŸ’Š **D-penicillamine:** **3086 days**  
   - âšª **Placebo:** **3428 days**  
ğŸ“‰ **Log-rank test:** *No significant difference* _(p = 0.5)_.  

### **Cox Proportional Hazards Model**  
âš ï¸ **Significant predictors affecting survival:**  
âœ… **Higher bilirubin â†’** **â†‘ Risk of mortality**  
âœ… **Higher albumin â†’** **â†“ Risk of mortality**  
âœ… **Presence of edema â†’** **â†‘ Risk** (_Severe cases more vulnerable!_)  
âœ… **Stage progression â†’** **â†‘ Risk**  
ğŸ“Œ **Treatment Effect:** No statistical difference _(p > 0.05)_ between **Placebo** & **D-penicillamine**.  

---

## ğŸ“‰ Visualizations  

### ğŸ” Kaplan-Meier Survival Curves  
![Kaplan-Meier Plot](https://via.placeholder.com/800x400.png?text=Kaplan-Meier+Survival+Curves)

### ğŸ“Š Cox Model Assumptions  
![Cox Model Assumptions](https://via.placeholder.com/800x400.png?text=Cox+Proportional+Hazards)

---

## ğŸ” Recommendations  

ğŸ’¡ **Clinical Actions for Improved Survival**  

ğŸ”¬ **Monitor Bilirubin & Albumin Levels Carefully**  
- ğŸ©¸ **Elevated bilirubin** signals higher risk â†’ Require aggressive intervention.  
- ğŸ½ **Higher albumin** improves survival â†’ Consider **nutritional therapy** support.  

âš ï¸ **Manage Edema Risks**  
- ğŸ¥ **Severe edema** raises mortality risk â†’ **Early treatment is critical!**  

ğŸ“Œ **Stage-Based Treatment Strategies**  
- Advanced stages significantly **increase risk** â†’ **Customized interventions per stage needed.**  

ğŸ’Š **Re-evaluate D-Penicillamine Usage**  
- ğŸ· No significant survival benefit over Placebo â†’ Consider alternative treatments.  

---

## ğŸš€ Getting Started  

### ğŸ”— **Prerequisites**  
Ensure you have **R** installed and the required libraries:  
```r
install.packages(c("survminer", "survival", "flexsurv", "tidyverse"))
